SCHEDULE: JPMorgan Reports Neurocrine Biosciences Stake

JPMorgan Chase & Co. has updated its Schedule 13G filing, reporting beneficial ownership of 5.2% of Neurocrine Biosciences, Inc. common stock as of September 30, 2026.

Summary

• JPMorgan Chase & Co. has filed an amended Schedule 13G, indicating a change in its beneficial ownership of Neurocrine Biosciences, Inc. common stock.
• As of September 30, 2026, JPMorgan Chase & Co. beneficially owns 5,300,390 shares, representing 5.2% of the class of securities.
• This filing is an amendment to a previous filing and is made in accordance with Rule 13d-1(b).
• The filing details the number of shares with sole and shared voting and dispositive power held by JPMorgan Chase & Co.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership by a financial institution without disclosing specific strategic reasons or significant shifts in investment thesis.

Positives

• JPMorgan Chase & Co. continues to hold a significant stake in Neurocrine Biosciences, Inc., indicating ongoing institutional interest.
• The filing provides clear and precise data on beneficial ownership, offering transparency to the market.

Negatives

• The filing does not provide specific reasons for the change in beneficial ownership, leaving the market to speculate on the underlying strategy.
• A 5.2% stake, while significant, does not represent a controlling interest and may not signal strong conviction from the reporting entity.

Risks

• Potential for further changes in beneficial ownership by large institutional holders could impact stock price volatility.
• The lack of detailed commentary in a Schedule 13G filing means that the market must infer the intent behind the ownership levels.

Future Outlook

This filing is a snapshot of beneficial ownership as of a specific date and does not contain forward-looking statements or guidance regarding future performance of Neurocrine Biosciences, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large financial institutions like JPMorgan Chase & Co. are common and often reflect routine portfolio management, market-making activities, or custodial roles rather than a specific strategic investment thesis in the underlying company.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional holdings, though the lack of specific commentary may lead to speculation.
• Market Participants: Provides data for analysis of institutional sentiment and ownership trends.

Next Steps

• Monitor future filings by JPMorgan Chase & Co. for any further changes in beneficial ownership.
• Observe market reaction and trading volumes for Neurocrine Biosciences, Inc. following this disclosure.

Key Dates

Keywords

Neurocrine Biosciences, JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing